http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Anixa Biosciences (ANIX) Treats Sixth Patient in its Ovarian Cancer CAR-T Trial
-
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences (ANIX) Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences (ANIX) Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
-
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
-
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
-
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
-
Anixa Biosciences (ANIX) Appoints Sanjay Juneja to its Cancer Business Advisory Board
-
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
-
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
-
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
-
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
-
Anixa Biosciences (ANIX) Granted Japanese Patent on Ovarian Cancer Vaccine Technology
-
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
-
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
-
Anixa Biosciences to Present at Biotech Showcase 2024
-
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
-
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
-
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
-
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
-
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
-
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences (ANIX) Issued Additional U.S. Patent for Ovarian Cancer Vaccine Technology
-
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
-
Anixa Biosciences Establishes Cancer Business Advisory Board
-
Anixa Biosciences to Participate in September Investor Conferences
-
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit
-
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
-
Anixa Biosciences (ANIX) Granted Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
-
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
-
Anixa Biosciences (ANIX) Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
-
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
-
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Clarifies Poster Presentation on Company Website
-
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
-
Anixa Biosciences (ANIX) Announces No Accounts at Silicon Valley Bank
-
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
-
Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
-
Anixa Biosciences (ANIX) Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
-
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
-
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
-
Anixa Biosciences to Present at Biotech Showcase 2023
-
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
-
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy
-
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic

